Literature DB >> 35200689

Adult Presentation of Subaortic Stenosis with Subaortic Membrane Treated with Surgical Removal.

Se Hun Kang1, In Jai Kim1, Won-Jang Kim1.   

Abstract

Subaortic stenosis (SAS) is a rare heart disease in adults with an unclear etiology and variable clinical presentation. In some cases, SAS appears as hypertrophic cardiomyopathy with obstruction due to the accompanying systolic anterior motion of the mitral valve. A 46-year-old male with dizziness for several months presented in the outpatient department. Two-dimensional transthoracic echocardiography demonstrated a slightly hypertrophic left ventricle with normal systolic function without wall-motion abnormalities. Just below the aortic valve, a linear structure protruding from the septum side and the left-ventricular outflow tract (LVOT) side of the mitral valve was confirmed, which was causing a significant pressure gradient (mean and maximum of 91 mmHg and 138 mmHg, respectively). A diagnosis of SAS with subaortic membrane was made, and surgical myomectomy and subaortic membrane removal surgery were performed. Postoperative transthoracic echocardiography did not show flow acceleration through the LVOT, nor a significant pressure gradient across the aortic valve. This case report highlights the clinical significance of SAS with subaortic membrane, which can be confused with aortic stenosis of other etiology.

Entities:  

Keywords:  aortic stenosis; aortic valve stenosis; subvalvular

Year:  2022        PMID: 35200689      PMCID: PMC8876706          DOI: 10.3390/jcdd9020036

Source DB:  PubMed          Journal:  J Cardiovasc Dev Dis        ISSN: 2308-3425


1. Introduction

Subaortic stenosis (SAS) is a rare heart disease in adults with an unclear etiology and variable clinical presentations. SAS usually develops during the first decade of life and might appear as an isolated lesion or in association with other congenital heart diseases [1]. SAS is most commonly described as a fibromuscular ring of tissue, but can also present as an incomplete shelf or ridge-like structure. The location of this structure can range from just below the aortic valve where it sometimes fuses with the leaflets, to lower within the LVOT where it can become attached to the anterior mitral valve leaflet. SAS usually follows a progressive course characterized by significant left-ventricular outflow tract (LVOT) obstruction, left-ventricular hypertrophy, and aortic valve destruction with subsequent regurgitation. In some cases, SAS appears as hypertrophic cardiomyopathy (HCM) with obstruction due to the accompanying systolic anterior motion of the mitral valve [2]. Although surgical treatment is successful in most cases, the recurrence rate is high, so continuous follow-up is required. We present a case of subaortic stenosis with subaortic membrane that was treated with surgical myomectomy and subaortic membrane removal surgery.

2. Case Presentation

A 46-year-old male presented to the outpatient department with dizziness he had been experiencing for several months. His medical history was unremarkable except for irritable bowel syndrome for years, and his vital signs were stable. Physical examination revealed a systolic murmur at the right-upper sternal border. Electrocardiography showed normal sinus rhythm with left-ventricular hypertrophy. Coronary computed tomography angiography showed no significant coronary artery stenosis, but a subaortic fibrotic membrane was observed. Two-dimensional transthoracic echocardiography demonstrated a normal-sized, slightly hypertrophic left ventricle with normal systolic function without wall-motion abnormalities. Just below the aortic valve, a linear structure protruding from the septum side and the LVOT side of the mitral valve was identified. Significant flow acceleration caused by these structures in the LVOT was seen, with a mean and maximal pressure gradient of 91 mmHg and 138 mmHg, respectively (Figure 1, Supplementary Videos S1 and S2). The aortic valve was tricuspid with a thickened leaflet, and mild aortic regurgitation was observed. Upon further inspection, dilatation of the ascending aorta with a diameter of 47 mm was detected. The patient was diagnosed as SAS with subaortic membrane, and surgical treatment was planned.
Figure 1

Transthoracic echocardiographic image showing a parasternal long-axis view (A,B), apical four-chamber view of the aortic valve (C), and continuous-wave Doppler across the aortic valve (D).

With the patient under general anesthesia, the aorta was opened transversely at the sino-tubular junction. Below the tricuspid aortic valve, an opening resembling a narrow gap made by the subaortic membrane was confirmed (Figure 2). The subvalvular membranes were resected, and a septal myomectomy was performed to enlarge the LVOT. Because there was an ascending aortic enlargement, ascending aorta wrapping was also performed. The pathology report of the resected membrane revealed myxoid degeneration with fibrosis. Postoperative transthoracic echocardiography did not show flow acceleration of the LVOT nor a significant pressure gradient across the aortic valve (Figure 3, Supplementary Videos S3 and S4). The patient was discharged in stable condition.
Figure 2

Surgical images of the aortic valve (A) and subaortic membrane (B).

Figure 3

Transthoracic echocardiographic image showing a parasternal long-axis view (A,B), apical four-chamber view of the aortic valve (C), and continuous-wave Doppler across the aortic valve (D) after subaortic membrane removal surgery.

3. Discussion

In this case, we reported on a case of a patient with SAS caused by subaortic membrane who was successfully treated by surgical removal. Subaortic stenosis is a form of LVOT obstruction that usually presents in the first 10 years of life as a progressive disease and is rare in adults with an unclear etiology [3]. In SAS, risk factors such as morphological LVOT abnormalities (e.g., sharp aortoseptal angle, subphysiologic aortic annulus diameter, and large aortic valve-mitral valve separation distance) are known to increase the risk of endocarditis [4]. Subaortic stenosis may be associated with other congenital anomalies, especially membranous ventricular septal defect that can occur in ≤65% of cases [1]. Other congenital anomalies include bicuspid aortic valve, coarctation of the aorta, and patent ductus arteriosus [5,6]. Patients with subaortic stenosis can range from asymptomatic to varying degrees of symptoms, including dyspnea at rest or with exertion, palpitation, chest pain, or syncope. SAS generally tends to progress slowly, with an annual increase in the gradient across the stenotic lesion. Without appropriate surgical intervention, SAS can progress to left ventricular hypertrophy and dysfunction, aortic regurgitation, endocarditis, arrythmias, and death. Echocardiography is preferred to diagnose SAS and to characterize the anatomy of the subaortic lesion, assess LVOT involvement, determine the dimensions and function of the LV, and determine the integrity of the aortic and mitral valves. Differentiating SAS from other causes of LVOT obstruction, especially HCM, can be difficult because some patients with SAS develop asymmetrical septal hypertrophy and secondary dynamic subaortic obstruction. The pressure gradient of subaortic stenosis may be underestimated or overestimated in the presence of a ventricular septal defect [3]. Currently, there are no established medical therapies, such as balloon dilation, to reverse or stop the progression of SAS. Thus, for patients with significant obstruction, surgical intervention is appropriate, but surgery can be considered at a lower pressure gradient if LV systolic dysfunction occurs due to left ventricular remodeling. Also, left ventricular remodeling is known to be associated with poor prognosis after surgery [6]. Surgical therapy for SAS consists of correction of the obstruction, which may involve simple membrane removal, extensive ring resection with or without myectomy, or a Konno procedure [7,8,9]. The timing of the surgery varies, with recommendations ranging from early operation to longer periods of observation depending on the patient’s characteristics. Survival after SAS surgery has been shown to be excellent. However, the LVOT gradient still increases slowly over time. Reoperation for recurrent discrete subaortic stenosis is commonly needed, with a reoperation rate between 6% and 30% [10]. The risk of reoperation may be due to inadequate resection at the first operation, yet recurrent obstruction may appear despite the adequacy of surgical excision. The risk of recurrent SAS is related to younger age at diagnosis and surgery, smaller aortic annulus, proximity of the obstruction to the aortic valve, and a higher preoperative peak LVOT gradient [11,12,13]. Females are have a 1.5 times higher risk of recurrence compared to males. This increased risk might be associated with a smaller LVOT anatomy in females [14]. In conclusion, subaortic stenosis remains a rare and clinically challenging diagnosis in adults, and its clinical presentation can closely mimic HCM with obstructive physiology. Therefore, a combination of imaging modalities is often needed to diagnose SAS with subaortic membrane and accompanying heart diseases. Although the standard treatment for subaortic stenosis is surgical correction, the recurrence rate is high, so regular echocardiographic follow-up is required.
  14 in total

1.  Surgical treatment results of secondary tunnel-like subaortic stenosis after congenital heart disease operations: A 7-year, single-center experience in 25 patients.

Authors:  Xing Zhang; Wei Wang; Jun Yan; Qiang Wang
Journal:  J Card Surg       Date:  2019-11-25       Impact factor: 1.620

2.  Preoperative Factors That Predict Recurrence After Repair of Discrete Subaortic Stenosis.

Authors:  Laura Carlson; Sarah Pickard; Kimberlee Gauvreau; Christopher Baird; Tal Geva; Pedro Del Nido; Meena Nathan
Journal:  Ann Thorac Surg       Date:  2020-07-23       Impact factor: 4.330

3.  Discrete membranous subaortic stenosis complicated by infective endocarditis: a case report.

Authors:  Emre Gurel; Tansu Karaahmet; Ali Cevat Tanalp; Bulent Mutlu; Yelda Basaran
Journal:  Heart Surg Forum       Date:  2007       Impact factor: 0.676

Review 4.  Subvalvular aortic stenosis: a review of current literature.

Authors:  Subodh R Devabhaktuni; Eyas Chakfeh; Ali O Malik; Joshua A Pengson; Jibran Rana; Chowdhury H Ahsan
Journal:  Clin Cardiol       Date:  2018-01-29       Impact factor: 2.882

5.  Discrete subaortic stenosis in adults: increased prevalence and slow rate of progression of the obstruction and aortic regurgitation.

Authors:  J M Oliver; A González; P Gallego; A Sánchez-Recalde; F Benito; J M Mesa
Journal:  J Am Coll Cardiol       Date:  2001-09       Impact factor: 24.094

6.  Long-term follow-up of subvalvular aortic stenosis in children: a single-centre experience.

Authors:  Mehmet G Ramoğlu; Selen Karagözlü; Tayfun Uçar; Zeynep Eyileten; Adnan Uysalel; Semra Atalay; Ercan Tutar
Journal:  Cardiol Young       Date:  2021-11-29       Impact factor: 1.093

7.  Risk factors for reoperation after repair of discrete subaortic stenosis in children.

Authors:  Alon Geva; Colin J McMahon; Kimberlee Gauvreau; Laila Mohammed; Pedro J del Nido; Tal Geva
Journal:  J Am Coll Cardiol       Date:  2007-09-24       Impact factor: 24.094

8.  A retrospective review in 50 patients with subaortic stenosis and intact ventricular septum: 5-year surgical experience.

Authors:  Reza Barkhordarian; Hideki Uemura; Michael L Rigby; Babulal Sethia; Darryl Shore; Aruna Goebells; Siew Yen Ho
Journal:  Interact Cardiovasc Thorac Surg       Date:  2006-10-17

9.  Adult presentation of subaortic stenosis: another great hypertrophic cardiomyopathy mimic.

Authors:  Ataul Qureshi; Stephen Awuor; Mathew Martinez
Journal:  Heart Lung Circ       Date:  2014-08-23       Impact factor: 2.975

10.  Long-term follow-up and outcomes of discrete subaortic stenosis resection in children.

Authors:  Lulu Abushaban; Babu Uthaman; John Puthur Selvan; Mustafa Al Qbandi; Prem N Sharma; Thinakar Vel Mariappa
Journal:  Ann Pediatr Cardiol       Date:  2019 Sep-Dec
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.